Combination cancer therapy: Presidential address.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000627:therapeutic use; D004261:DNA Replication / Q000187:drug effects; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007165:Immunosuppression Therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011379:Prognosis; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine